ArrowMark Colorado Holdings LLC Lowers Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

ArrowMark Colorado Holdings LLC lessened its position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 13.4% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 882,731 shares of the biopharmaceutical company’s stock after selling 136,626 shares during the period. ArrowMark Colorado Holdings LLC’s holdings in Agios Pharmaceuticals were worth $39,220,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of AGIO. Caxton Associates LP raised its holdings in Agios Pharmaceuticals by 0.7% in the 2nd quarter. Caxton Associates LP now owns 37,453 shares of the biopharmaceutical company’s stock valued at $1,615,000 after acquiring an additional 264 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Agios Pharmaceuticals by 6.0% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,132 shares of the biopharmaceutical company’s stock worth $539,000 after buying an additional 688 shares during the period. Acadian Asset Management LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter worth about $37,000. Finally, Quest Partners LLC purchased a new stake in Agios Pharmaceuticals in the 2nd quarter valued at about $40,000.

Insider Buying and Selling

In other Agios Pharmaceuticals news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the sale, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. This represents a 11.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 4.93% of the company’s stock.

Agios Pharmaceuticals Stock Up 1.2 %

AGIO stock opened at $59.39 on Monday. The company has a market capitalization of $3.39 billion, a PE ratio of 5.23 and a beta of 0.75. The stock’s 50 day moving average is $48.68 and its two-hundred day moving average is $45.49. Agios Pharmaceuticals, Inc. has a 52-week low of $20.96 and a 52-week high of $62.58.

Analyst Upgrades and Downgrades

AGIO has been the topic of several recent analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $55.00 price objective on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Scotiabank upped their price objective on Agios Pharmaceuticals from $51.00 to $53.00 and gave the stock a “sector outperform” rating in a report on Friday, November 1st. Leerink Partners lowered Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $60.00 to $56.00 in a research report on Friday, September 27th. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Friday, September 20th. Finally, Raymond James restated an “outperform” rating and issued a $51.00 price objective on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $52.33.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.